Johnson & Johnson (NYSE:JNJ) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. lessened its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,254,997 shares of the company's stock after selling 80,679 shares during the quarter. Victory Capital Management Inc. owned 0.09% of Johnson & Johnson worth $353,448,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. 4J Wealth Management LLC increased its position in shares of Johnson & Johnson by 2.2% during the fourth quarter. 4J Wealth Management LLC now owns 2,835 shares of the company's stock worth $444,000 after purchasing an additional 62 shares in the last quarter. My Personal CFO LLC increased its position in Johnson & Johnson by 1.4% during the 4th quarter. My Personal CFO LLC now owns 4,550 shares of the company's stock valued at $713,000 after buying an additional 62 shares in the last quarter. Eagle Strategies LLC boosted its holdings in Johnson & Johnson by 1.8% in the fourth quarter. Eagle Strategies LLC now owns 3,589 shares of the company's stock worth $563,000 after acquiring an additional 63 shares in the last quarter. Clearview Wealth Advisors LLC grew its stake in shares of Johnson & Johnson by 1.5% during the fourth quarter. Clearview Wealth Advisors LLC now owns 4,373 shares of the company's stock worth $685,000 after acquiring an additional 64 shares during the last quarter. Finally, Brookmont Capital Management increased its holdings in shares of Johnson & Johnson by 0.4% during the fourth quarter. Brookmont Capital Management now owns 14,852 shares of the company's stock valued at $2,328,000 after acquiring an additional 64 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

NYSE JNJ traded down $0.70 on Monday, hitting $148.57. The company had a trading volume of 5,042,259 shares, compared to its average volume of 7,441,139. The company's fifty day moving average price is $153.95 and its 200-day moving average price is $155.00. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97. The company has a market capitalization of $357.56 billion, a PE ratio of 9.26, a PEG ratio of 2.46 and a beta of 0.55. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.64 by $0.07. The company had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. Johnson & Johnson's quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.68 EPS. As a group, analysts predict that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be paid a $1.24 dividend. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a dividend yield of 3.34%. The ex-dividend date of this dividend is Monday, May 20th. Johnson & Johnson's dividend payout ratio (DPR) is currently 29.68%.

Insider Activity at Johnson & Johnson

In other news, major shareholder & Johnson Johnson sold 3,725 shares of the business's stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares of the company's stock, valued at approximately $105,810,030.75. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the firm's stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares of the company's stock, valued at $105,810,030.75. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Jennifer L. Taubert sold 59,397 shares of the company's stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Bank of America dropped their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 17th. Morgan Stanley lowered their price target on Johnson & Johnson from $168.00 to $167.00 and set an "equal weight" rating for the company in a research report on Wednesday, April 17th. Cantor Fitzgerald restated an "overweight" rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Monday. HSBC upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating and increased their price target for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. Finally, StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Tuesday, February 6th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $175.86.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.